89bio Beheer
Beheer criteriumcontroles 2/4
89bio's CEO is Rohan Palekar, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.59M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $2.60M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.
Belangrijke informatie
Rohan Palekar
Algemeen directeur
US$5.6m
Totale compensatie
Percentage CEO-salaris | 10.9% |
Dienstverband CEO | 6.3yrs |
Eigendom CEO | 0.3% |
Management gemiddelde ambtstermijn | 3.3yrs |
Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
Jan 2289bio expects to initiate Phase 2b NASH trial in 1H21
Jan 05Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$175m |
Mar 31 2024 | n/a | n/a | -US$165m |
Dec 31 2023 | US$6m | US$611k | -US$142m |
Sep 30 2023 | n/a | n/a | -US$127m |
Jun 30 2023 | n/a | n/a | -US$119m |
Mar 31 2023 | n/a | n/a | -US$105m |
Dec 31 2022 | US$3m | US$588k | -US$102m |
Sep 30 2022 | n/a | n/a | -US$104m |
Jun 30 2022 | n/a | n/a | -US$105m |
Mar 31 2022 | n/a | n/a | -US$101m |
Dec 31 2021 | US$5m | US$565k | -US$90m |
Sep 30 2021 | n/a | n/a | -US$76m |
Jun 30 2021 | n/a | n/a | -US$63m |
Mar 31 2021 | n/a | n/a | -US$54m |
Dec 31 2020 | US$5m | US$530k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$56m |
Jun 30 2020 | n/a | n/a | -US$60m |
Mar 31 2020 | n/a | n/a | -US$64m |
Dec 31 2019 | US$1m | US$431k | -US$57m |
Sep 30 2019 | n/a | n/a | -US$44m |
Jun 30 2019 | n/a | n/a | -US$30m |
Dec 31 2018 | US$708k | US$195k | -US$18m |
Compensatie versus markt: Rohan's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.24M).
Compensatie versus inkomsten: Rohan's compensation has increased whilst the company is unprofitable.
CEO
Rohan Palekar (58 yo)
6.3yrs
Tenure
US$5,587,661
Compensatie
Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 6.3yrs | US$5.59m | 0.27% $ 2.6m | |
Chief Technical Officer | 5.7yrs | US$2.51m | 0.15% $ 1.4m | |
Chief Medical Officer | 5.9yrs | US$2.54m | 0.088% $ 854.6k | |
Chief Financial Officer | 5.3yrs | geen gegevens | 0.042% $ 409.8k | |
Chief Operating Officer | less than a year | geen gegevens | geen gegevens | |
Senior Vice President of Finance & Principal Accounting Officer | no data | geen gegevens | geen gegevens | |
VP of Investor Relations & Corporate Communications | less than a year | geen gegevens | geen gegevens | |
Vice President of People & Culture | 3.8yrs | geen gegevens | geen gegevens | |
Senior Vice President of Commercial Strategy | no data | geen gegevens | geen gegevens | |
Senior Vice President of R&D Operations | 2.8yrs | geen gegevens | geen gegevens | |
Senior VP & Head of Quality | 1.8yrs | geen gegevens | geen gegevens | |
Chief Regulatory & Quality Officer | less than a year | geen gegevens | geen gegevens |
3.3yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: ETNB's management team is considered experienced (3.3 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 6.3yrs | US$5.59m | 0.27% $ 2.6m | |
Independent Director | 3yrs | US$360.17k | 0% $ 0 | |
Independent Director | 4.3yrs | US$363.33k | 0% $ 0 | |
Independent Director | 6.6yrs | US$358.33k | 0.23% $ 2.3m | |
Independent Director | less than a year | geen gegevens | geen gegevens | |
Independent Chairman of the Board | 4.7yrs | US$385.83k | 0% $ 0 | |
Director | less than a year | geen gegevens | geen gegevens | |
Independent Director | 2.8yrs | US$354.60k | 0% $ 0 | |
Independent Director | 6.6yrs | US$352.33k | 0% $ 0 |
4.3yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: ETNB's board of directors are considered experienced (4.3 years average tenure).